Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc.verified

VRCA

Price:

$0.6859

Market Cap:

$62.12M

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagio...[Read more]

Industry

Biotechnology

IPO Date

2018-06-15

Stock Exchange

NASDAQ

Ticker

VRCA

The PE Ratio as of December 2024 (TTM) for Verrica Pharmaceuticals Inc. (VRCA) is -0.37

According to Verrica Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.37. This represents a change of -88.57% compared to the average of -3.24 of the last 4 quarters.

Verrica Pharmaceuticals Inc. (VRCA) Historical PE Ratio (quarterly & annually)

How has VRCA PE Ratio performed in the past?

The mean historical PE Ratio of Verrica Pharmaceuticals Inc. over the last ten years is -37.72. The current -0.37 PE Ratio has changed -1.90% with respect to the historical average. Over the past ten years (40 quarters), VRCA's PE Ratio was at its highest in in the September 2022 quarter at 354.49. The PE Ratio was at its lowest in in the March 2017 quarter at -153.10.

Quarterly (TTM)
Annual

Average

-37.72

Median

-6.35

Minimum

-182.47

Maximum

-3.39

Verrica Pharmaceuticals Inc. (VRCA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Verrica Pharmaceuticals Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 144.57%

Maximum Annual PE Ratio = -3.39

Minimum Annual Increase = -92.61%

Minimum Annual PE Ratio = -182.47

Quarterly (TTM)
Annual
YearPE RatioChange
2023-4.9545.95%
2022-3.39-46.69%
2021-6.370.70%
2020-6.32-55.33%
2019-14.15144.57%
2018-5.79-92.61%
2017-78.28-57.10%

Verrica Pharmaceuticals Inc. (VRCA) Average PE Ratio

How has VRCA PE Ratio performed in the past?

The current PE Ratio of Verrica Pharmaceuticals Inc. (VRCA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.91

5-year avg

-7.04

10-year avg

-37.72

Verrica Pharmaceuticals Inc. (VRCA) PE Ratio vs. Peers

How is VRCA’s PE Ratio compared to its peers?

Verrica Pharmaceuticals Inc.’s PE Ratio is greater than LianBio (-0.75), greater than Inventiva S.A. (-1.12), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Vigil Neuroscience, Inc. (-0.80), less than Connect Biopharma Holdings Limited (7.21), greater than Acumen Pharmaceuticals, Inc. (-1.32), greater than Eton Pharmaceuticals, Inc. (-59.82), greater than Nuvation Bio Inc. (-1.45), less than Eledon Pharmaceuticals, Inc. (18.27), greater than Verona Pharma plc (-23.85), less than Galera Therapeutics, Inc. (-0.08), greater than Arcutis Biotherapeutics, Inc. (-9.53), greater than Protalix BioTherapeutics, Inc. (-13.55), greater than Chinook Therapeutics, Inc. (-14.08), greater than DICE Therapeutics, Inc. (-22.94), greater than Pliant Therapeutics, Inc. (-4.06), greater than Crinetics Pharmaceuticals, Inc. (-15.54), greater than Ascendis Pharma A/S (-17.81), greater than Fennec Pharmaceuticals Inc. (-140.49), greater than Larimar Therapeutics, Inc. (-3.72), less than Homology Medicines, Inc. (-0.01),

Build a custom stock screener for Verrica Pharmaceuticals Inc. (VRCA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Verrica Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Verrica Pharmaceuticals Inc. (VRCA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Verrica Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Verrica Pharmaceuticals Inc.'s PE Ratio?

How is the PE Ratio calculated for Verrica Pharmaceuticals Inc. (VRCA)?

What is the highest PE Ratio for Verrica Pharmaceuticals Inc. (VRCA)?

What is the 3-year average PE Ratio for Verrica Pharmaceuticals Inc. (VRCA)?

What is the 5-year average PE Ratio for Verrica Pharmaceuticals Inc. (VRCA)?

How does the current PE Ratio for Verrica Pharmaceuticals Inc. (VRCA) compare to its historical average?